For Immediate Release
Dr. Anthony Fauci Reflects on His 54 Year Career at NIH in Exclusive Interview
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, November 15, 2022—Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, shares his thoughts on the COVID-19 pandemic, HIV/AIDS, and his long career at the NIH in an exclusive new interview in the peer-reviewed journal Viral Immunology. Click here to read the interview now.
In the interview, Rodney S. Russell, PhD, Editor-in-Chief of Viral Immunology, asks Dr. Fauci how the COVID-19 pandemic has affected vaccine literacy in North America and globally, and what he feels was the most unexpected aspect of the pandemic.
Regarding HIV/AIDS, Dr. Fauci emphasizes “The terminology of undetectable equals untransmittable. That is a major advance. What we have done now over the last few years is to make the therapeutic approach much easier and user friendly, such as with long-acting injectable drugs, which can be given every couple of months. And I believe as we get better at it over the coming months and years, it may be that you can give an injectable drug maybe twice a year and continue to suppress the virus below detectable level.”
Dr. Fauci will step down as Director of the NIAID at the end of the year, after 38 years in that position. Looking back, he notes, “I developed and nurtured the institute from a small institute of a budget of approximately $350 million to an infectious diseases global powerhouse of $6.3 billion. In addition, as Director, I developed the AIDS program at the institute, which actually is responsible in part for the development of life-saving drugs that have been responsible, essentially, for transforming the lives of persons with HIV throughout the world.”
About the Journal
Viral Immunology is an authoritative peer-reviewed journal published ten times a year in print and online. Topics cover both human and animal viral immunology, exploring viral-based immunological diseases, pathogenic mechanisms, and virus-associated tumor and cancer immunology. The Journal includes original research papers, review articles, and commentaries covering the spectrum of laboratory and clinical research and exploring developments in vaccines and diagnostics targeting viral infections. Tables of content and a sample issue may be viewed on the Viral Immunology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s more than 100 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.